We obsess about model size, latency and accuracy – but too often forget the systems that actually allow AI to run in the wild inside regulated organisations. The real barrier to enterprise AI adoption in life sciences isn’t just capability; it’s the friction of making AI auditable, validated and trustworthy for regulators and internal quality teams.
Context
I recently read about a startup, Iridius, that is taking a different tack: rather than monitoring AI workflows after the fact, they aim to translate regulations and corporate policy into executable rules so compliance is enforced at runtime and every agent action is logged for audit. Their initial focus is life sciences – a domain where the cost of failing compliance is existential.
Analysis – the architectural implications
What Iridius’ approach highlights is a broader architectural shift that I’ve been recommending to enterprise CTOs for years: treat compliance as first-class runtime behaviour, not as a post-hoc reporting requirement.
Three technical implications matter for any organisation attempting this:
– Policy-as-code becomes essential. Encoding regulatory requirements into machine-readable rules lets you automate approvals, guardrails and exception handling. But policy-as-code is not free: it requires continuous interpretation of regulatory text, traceability to the source regulation, and a governance loop that keeps rules aligned with legal opinion and SOP changes.
– Observability must be designed for audit, not just incident response. Traditional observability focuses on metrics and traces for ops teams. In regulated AI deployments you also need immutable, queryable provenance of data inputs, model versions, prompt templates, agent actions and human overrides. This data must be tamper-evident and simple to present in a regulatory inspection.
– Shift-left validation and modular architectures. If compliance is enforced at runtime, you reduce downstream surprises – but only if modelling, test harnesses and CI/CD pipelines are extended to validate policies, data lineage and explainability properties before deployment. This favors microservices and clear contract boundaries so compliance controls can be composed and reused across workflows.
Trade-offs and the build vs buy question
There’s a real trade-off between bespoke in-house controls and integrated platforms: building gives you tight alignment to internal SOPs but creates long-term maintenance debt (regulation translations, audit templates, evidence packages). Buying or partnering with vendors that provide codified compliance accelerates time-to-value but requires rigorous due-diligence: can the vendor map rules to your jurisdictional obligations? How do they handle divergent interpretations across countries and business units?
For many pharma and regulated enterprises a hybrid model works best: adopt vendor policy engines and runtime enforcement but keep a governance layer internally that owns mapping, sign-off and audit evidence. Co-development agreements – exactly the type of partnership the startup I read about is pursuing – are a sensible way to bridge domain expertise with platform engineering.
Practical actions for CTOs and Founders
– Start with the highest-risk workflows and codify only what materially affects safety, efficacy, or regulatory standing. Small wins demonstrate ROI and buy executive sponsorship.
– Extend CI/CD to include policy and evidence tests: policy-unit tests, lineage checks, and reproducibility runs that produce audit-ready packages.
– Design immutable audit trails and clearly separate human-in-the-loop decisions. Ensure your HCI captures rationale and approvals when exceptions are allowed.
– Prioritise integrations with the systems of record used by the domain (e.g., clinical data management, LIMS, Veeva-like vendors) rather than attempting to replace them.
– Invest in governance capability: legal, quality, and subject-matter experts must be part of the rules lifecycle.
A Bharat/Northeast perspective (brief)
India is home to major pharmaceutical manufacturers, CROs and an expanding clinical-trial ecosystem. The same architectural principles apply: policy-as-code and auditable AI reduce inspection risk and improve global market access. For startups and state digital programmes in the Northeast, prioritising composable, auditable AI components will make solutions export-ready and regulator-friendly.
Takeaways
Embedding compliance into execution changes the cost curve of AI adoption: it raises upfront engineering effort but dramatically lowers the operational and regulatory friction that kills pilots. The right mix of policy-as-code, lineage-first observability and governance is the practical path from prototype to production in regulated industries.
Closing thought
AI’s next big multiplier won’t be bigger models – it will be systems that let organisations run AI with confidence under the gaze of regulators and auditors.
About the Author Sanjeev Sarma is the Founder Director of Webx Technologies Private Limited, a leading Technology Consulting firm with over two decades of experience. A seasoned technology strategist and Chief Software Architect, he specializes in Enterprise Software Architecture, Cloud-Native Applications, AI-Driven Platforms, and Mobile-First Solutions. Recognized as a “Technology Hero” by Microsoft for his pioneering work in e-Governance, Sanjeev actively advises state and central technology committees, including the Advisory Board for Software Technology Parks of India (STPI) across multiple Northeast Indian states. He is also the Managing Editor for Mahabahu.com, an international journal. Passionate about fostering innovation, he actively mentors aspiring entrepreneurs and leads transformative digital solutions for enterprises and government sectors from his base in Northeast India.
